Telehealth stocks pressured as Amazon Pharmacy expands prescription delivery

Investing.com -- Amazon.com Inc (NASDAQ: AMZN) intensified its push into the healthcare sector Wednesday, announcing a massive logistics expansion that sent shockwaves through the digital health market. The retail giant plans to scale its same-day prescription delivery service to nearly 4,500 cities and towns by the end of 2026.

The move aims to bridge gaps left by a national wave of pharmacy closures and chronic staffing shortages in traditional retail settings. Amazon will introduce this rapid service to new territories, including Idaho and Massachusetts, over the coming year.

The company is leveraging its vast logistics network to deploy specialized delivery methods, ranging from e-bikes in Manhattan to ferries and horses on Mackinac Island. "By combining our pharmacy expertise with our logistics network, we’re removing critical barriers and helping patients start treatment faster," said John Love, vice president of Amazon Pharmacy.

This logistical prowess is increasingly viewed as a structural threat to standalone telehealth platforms that lack similar physical distribution power. "Patients shouldn’t have to choose between speed, cost, and convenience when it comes to their medication, regardless of where they live," Love added

The announcement triggered a sharp sell-off across the telehealth sector, with shares of Teladoc Inc (NYSE: TDOC) and Doximity Inc (NYSE: DOCS) falling 5.8% and 2.9%, respectively. Investors have expressed concern that Amazon’s "digital-forward" pharmacy model will commoditize the patient-provider relationship held by smaller firms.

Hims Hers Health Inc (NYSE: HIMS) also saw its stock decline 2.3%, compounding a week of heavy losses driven by regulatory scrutiny over its GLP-1 weight-loss pill offerings. The company recently faced a patent infringement lawsuit from Novo Nordisk and increasing pressure from the Food and Drug Administration.

Simultaneously, Amazon is deepening its clinical capabilities through its One Medical subsidiary by launching a new beta feature called Health Insights. This tool uses AI to analyze more than 50 biomarkers from routine bloodwork, providing patients with personalized health recommendations.

The feature is designed to transform complex lab data into actionable lifestyle guidance while keeping human providers at the center of the care model. "Health Insights brings clarity to complex health data and gives providers another way to help our members understand what their lab results mean," said Andrew Diamond, Chief Medical Officer at Amazon One Medical.

The market volatility follows the recent launch of TrumpRx, a government-sponsored drug discount portal that is currently powered by GoodRx. Despite this partnership, GoodRx shares fell 3% amid the Amazon news, following a Stat News report from last week noting that many brand-name drugs on the TrumpRx platform have cheaper generics available elsewhere.

The combination of Amazon’s expansion, heightened regulatory scrutiny, and new federal pricing initiatives has left traditional digital health players in a defensive crouch. Market participants seem to be reassessing the long-term viability of independent telehealth models as Amazon scales its integrated healthcare ecosystem.

You May Also Be Interested In

• Jefferies sees signs of softer iPhone 18 demand
• Lagarde says moderate ECB policy response remains appropriate
• TD Cowen highlights top oil stocks ahead of earnings season